The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of CRISPR Therapeutics AG (NASDAQ: CRSP) was $50.72 for the day, up 0.71% from the previous closing price of $50.36. In other words, the price has increased by $0.71 from its previous closing price. On the day, 2.27 million shares were traded. CRSP stock price reached its highest trading level at $51.79 during the session, while it also had its lowest trading level at $49.3901.
Ratios:
Our analysis of CRSP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 21.64 and its Current Ratio is at 21.64. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on August 06, 2024, Reiterated its Buy rating but revised its target price to $84 from $88 previously.
On August 02, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $90.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 14 ’24 when KASINGER JAMES R. sold 1,089 shares for $46.28 per share. The transaction valued at 50,399 led to the insider holds 62,597 shares of the business.
Kulkarni Samarth sold 4,293 shares of CRSP for $198,680 on Oct 14 ’24. The Chief Executive Officer now owns 226,540 shares after completing the transaction at $46.28 per share. On Jun 21 ’24, another insider, Bruno Julianne, who serves as the Chief Operating Officer of the company, sold 3,366 shares for $56.09 each. As a result, the insider received 188,799 and left with 6,745 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 4329129984 and an Enterprise Value of 2538341120. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.30 while its Price-to-Book (P/B) ratio in mrq is 2.23. Its current Enterprise Value per Revenue stands at 12.552 whereas that against EBITDA is -7.573.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $43.42. The 50-Day Moving Average of the stock is 7.26%, while the 200-Day Moving Average is calculated to be -12.52%.
Shares Statistics:
CRSP traded an average of 1.11M shares per day over the past three months and 1541560 shares per day over the past ten days. A total of 85.17M shares are outstanding, with a floating share count of 81.47M. Insiders hold about 4.35% of the company’s shares, while institutions hold 65.91% stake in the company. Shares short for CRSP as of 1728950400 were 17592960 with a Short Ratio of 15.90, compared to 1726185600 on 17543484. Therefore, it implies a Short% of Shares Outstanding of 17592960 and a Short% of Float of 23.419999999999998.
